Meeting
2022 ASCO Annual Meeting
A phase II study, with a safety lead-in, to evaluate ATX-101, a peptide drug targeting PCNA, in advanced dedifferentiated liposarcoma and leiomyosarcoma.
Authors
Sminu Bose
Columbia University Irving Medical Center, New York, NY
Sminu Bose , Matthew Ingham , Shahnaz V. Singh-Kandah , Wendy Magana , Gary K. Schwartz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Molecular Targets/Biomarkers/Tumor Biology
Clinical Trial Registration Number
NCT05116683
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS11587)
DOI
10.1200/JCO.2022.40.16_suppl.TPS11587
Abstract #
TPS11587
Poster Bd #
488b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.
First Author: Sminu (Sam) Bose
Poster
2023 ASCO Annual Meeting
Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).
First Author: Xi Guo
Poster
2023 ASCO Annual Meeting
Interim results of a phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma.
First Author: Neal Shiv Chawla
First Author: Sujana Movva